Home Blog of Signal Transduction PI3K/Akt/mTOR Raf MAPK cascade promotes early axonal degeneration in response to injury

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

MAPK cascade promotes early axonal degeneration in response to injury

 

Axons connect neurons are essential for neural circuits formation. The death of axon is associated to many neurodegenerative disorders including traumatic injury. By using traumatic injury as a model, Yang et al. demonstrated a critical role of mitogen-activated protein kinase (MAPK) cascade in early axonal degeneration in response to injury. The article was published on Cell, recently.

 

Previous studies showed the suppression of Sarm1, a Toll receptor adaptor protein, significantly delays axonal degeneration after injury. Researchers found Sarm1, in response to early axonal injury, is required for the activation of MAPK cascade, which leads to disruption of local energy homeostasis, ATP depletion, activation of calpains, at last, breakdown of axonal structures. They found a central regulatory factor of MAPK pathway, MAPK kinase 4 (MKK4), limits activation of downstream molecule c-Jun N-terminal kinases (JNKs) to modulate early injury response. Furthermore, a cytosolic version of nocotinamide mononucleotide adenylyltransferase 1 (Nmnat1), which is related to NAD+ synthesis, was found to inhibit the MAPK pathway activation. In conclusion, the findings reveal a novel MAPK pathway-centered regulatory mechanism in promoting pathological axon degeneration through inducing local energy deficit.

 

Reference:
Cell. 2015 Jan 15;160(1-2):161-76.

Related Products

Cat.No. Product Name Information
S1036 Mirdametinib (PD0325901) Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
S1152 PLX-4720 PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
S1078 MK-2206 2HCl MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.
S2808 Ipatasertib (GDC-0068) Ipatasertib (GDC-0068, RG7440) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

Related Targets

Raf MEK Akt